<p>苏黎世州立银行在其最近向证券交易委员会提交的文件中表示，在第三季度将其在 Dynavax Technologies Co.（纳斯达克代码：DVAX - 免费报告）的股份减少了 78.1%。该基金在此期间出售了 92,157 股后，持有 25,880 股该生物制药公司的股票。根据其最近向证券交易委员会提交的文件，苏黎世州立银行在 Dynavax Technologies 的持股价值为 288,000 美元。</p>
<p>获取 <strong>Dynavax Technologies</strong> 警报：</p>
<p>其他一些对冲基金和机构投资者最近也买卖了该股票的股份。Renaissance Technologies LLC 在第二季度将其在 Dynavax Technologies 的股份增加了 2.2%。Renaissance Technologies LLC 现在拥有 2,478,178 股该生物制药公司的股票，价值 27,830,000 美元，此前在上个季度又购买了 53,600 股。Great Point Partners LLC 在第二季度将其在 Dynavax Technologies 的持仓增加了 87.7%。Great Point Partners LLC 现在拥有 2,374,000 股该生物制药公司的股票，价值 26,660,000 美元，此前在上个季度又购买了 1,109,080 股。Millennium Management LLC 在第二季度购买了 Dynavax Technologies 的新股份，估值为 17,615,000 美元。Mizuho Markets Americas LLC 在第三季度将其在 Dynavax Technologies 的股份增加了 17.4%。Mizuho Markets Americas LLC 现在拥有 1,379,582 股该生物制药公司的股票，价值 15,369,000 美元，此前在上个季度又收购了 204,475 股。最后，加拿大蒙特利尔银行在第三季度将其在 Dynavax Technologies 的持股增加了 8.3%。加拿大蒙特利尔银行现在拥有 1,077,081 股该生物制药公司的股票，价值 11,848,000 美元，此前在此期间又收购了 82,449 股。96.96% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Dynavax Technologies 价格表现</h2>
<p>Dynavax Technologies 的股票在周一开盘价为 12.85 美元。该公司的速动比率为 12.34，流动比率为 13.23，债务与股本比率为 0.33。Dynavax Technologies Co.的 52 周最低价为 9.74 美元，52 周最高价为 15.01 美元。该公司的市值为 16.9 亿美元，市盈率为 98.85，贝塔值为 1.33。该公司的 50 日移动平均线为 11.85 美元，200 日移动平均线为 11.44 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，HC Wainwright 在 11 月 8 日的研究报告中重申了对 Dynavax Technologies 的 “买入” 评级，并给出了 29.00 美元的目标价。</p>
<p><strong>查看我们对 Dynavax Technologies 的最新股票分析</strong></p>
<h2>Dynavax Technologies 公司简介</h2>
<p>（免费报告）</p>
<p>Dynavax Technologies Corporation 是一家商业阶段的生物制药公司，专注于在美国开发和商业化疫苗。它在美国和欧洲市场销售 HEPLISAV-B，这是一种用于预防所有已知亚型的乙型肝炎病毒感染的乙型肝炎疫苗，适用于 18 岁及以上人群。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Dynavax Technologies</li>
<li>股息捕获策略：你需要知道的事项</li>
<li>Guidewire Software 提供了期待已久的购买机会</li>
<li>什么是欧元 STOXX 50 指数？</li>
<li>最近这三项分析师股票升级背后的原因是什么？</li>
<li>投资石油股票的方式和原因</li>
<li>仍被低估的快速增长公司</li>
</ul>
<p><strong>想看看其他对冲基金持有的 DVAX 吗？</strong> 访问 HoldingsChannel.com 获取 Dynavax Technologies Co.（纳斯达克代码：DVAX - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<p>→ 马斯克的新公司可能超过一万亿？（来自 Paradigm Press）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDY3Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDY3Mg"/></p>
<h2>你现在应该投资 1,000 美元在 Dynavax Technologies 吗？</h2>
<p>在考虑 Dynavax Technologies 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Dynavax Technologies 并不在名单上。</p>
<p>虽然 Dynavax Technologies 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

德纳维制药

<p>苏黎世州立银行在第三季度将其在 Dynavax Technologies Co.（NASDAQ:DVAX）的持股减少了 78.1%，目前持有 25,880 股，出售了 92,157 股。其他机构投资者，包括文艺复兴科技和 Great Point Partners，也调整了他们的持仓。Dynavax Technologies 的市值为 16.9 亿美元，市盈率为 98.85。分析师维持 “买入” 评级，目标价为 10.00 美元。该公司专注于开发疫苗，包括用于乙型肝炎的 HEPLISAV-B</p>

<p>Zurcher Kantonalbank Zurich Cantonalbank lessened its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 78.1% in the 3rd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 25,880 shares of the biopharmaceutical company's stock after selling 92,157 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Dynavax Technologies were worth $288,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>苏黎世州立银行在其最近向证券交易委员会提交的文件中表示，在第三季度将其在 Dynavax Technologies Co.（纳斯达克代码：DVAX - 免费报告）的股份减少了 78.1%。该基金在此期间出售了 92,157 股后，持有 25,880 股该生物制药公司的股票。根据其最近向证券交易委员会提交的文件，苏黎世州立银行在 Dynavax Technologies 的持股价值为 288,000 美元。</p>
</div><p>Get <strong>Dynavax Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Dynavax Technologies</strong> 警报：</p>
</div><p>A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in Dynavax Technologies by 2.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company's stock worth $27,830,000 after purchasing an additional 53,600 shares in the last quarter. Great Point Partners LLC lifted its position in Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company's stock worth $26,660,000 after buying an additional 1,109,080 shares in the last quarter. Millennium Management LLC purchased a new stake in Dynavax Technologies in the 2nd quarter valued at $17,615,000. Mizuho Markets Americas LLC increased its stake in shares of Dynavax Technologies by 17.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company's stock worth $15,369,000 after acquiring an additional 204,475 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock worth $11,848,000 after acquiring an additional 82,449 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也买卖了该股票的股份。Renaissance Technologies LLC 在第二季度将其在 Dynavax Technologies 的股份增加了 2.2%。Renaissance Technologies LLC 现在拥有 2,478,178 股该生物制药公司的股票，价值 27,830,000 美元，此前在上个季度又购买了 53,600 股。Great Point Partners LLC 在第二季度将其在 Dynavax Technologies 的持仓增加了 87.7%。Great Point Partners LLC 现在拥有 2,374,000 股该生物制药公司的股票，价值 26,660,000 美元，此前在上个季度又购买了 1,109,080 股。Millennium Management LLC 在第二季度购买了 Dynavax Technologies 的新股份，估值为 17,615,000 美元。Mizuho Markets Americas LLC 在第三季度将其在 Dynavax Technologies 的股份增加了 17.4%。Mizuho Markets Americas LLC 现在拥有 1,379,582 股该生物制药公司的股票，价值 15,369,000 美元，此前在上个季度又收购了 204,475 股。最后，加拿大蒙特利尔银行在第三季度将其在 Dynavax Technologies 的持股增加了 8.3%。加拿大蒙特利尔银行现在拥有 1,077,081 股该生物制药公司的股票，价值 11,848,000 美元，此前在此期间又收购了 82,449 股。96.96% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Dynavax Technologies Price Performance</h2>
<div class="lb-trans"><h2>Dynavax Technologies 价格表现</h2>
</div><p>Dynavax Technologies stock opened at $12.85 on Monday. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The firm has a market cap of $1.69 billion, a PE ratio of 98.85 and a beta of 1.33. The company's 50 day moving average is $11.85 and its two-hundred day moving average is $11.44.</p>
<div class="lb-trans"><p>Dynavax Technologies 的股票在周一开盘价为 12.85 美元。该公司的速动比率为 12.34，流动比率为 13.23，债务与股本比率为 0.33。Dynavax Technologies Co.的 52 周最低价为 9.74 美元，52 周最高价为 15.01 美元。该公司的市值为 16.9 亿美元，市盈率为 98.85，贝塔值为 1.33。该公司的 50 日移动平均线为 11.85 美元，200 日移动平均线为 11.44 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, HC Wainwright reissued a &#34;buy&#34; rating and issued a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, November 8th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 11 月 8 日的研究报告中重申了对 Dynavax Technologies 的 “买入” 评级，并给出了 29.00 美元的目标价。</p>
</div><p><strong>View Our Latest Stock Analysis on Dynavax Technologies</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Dynavax Technologies 的最新股票分析</strong></p>
</div><h2>Dynavax Technologies Company Profile</h2>
<div class="lb-trans"><h2>Dynavax Technologies 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.</p>
<div class="lb-trans"><p>Dynavax Technologies Corporation 是一家商业阶段的生物制药公司，专注于在美国开发和商业化疫苗。它在美国和欧洲市场销售 HEPLISAV-B，这是一种用于预防所有已知亚型的乙型肝炎病毒感染的乙型肝炎疫苗，适用于 18 岁及以上人群。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Dynavax Technologies</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Guidewire Software Provides Long-Awaited Buying Opportunity</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>What’s Behind These 3 Recent Analyst Stock Upgrades?</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Fast-Growing Companies That Are Still Undervalued</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Dynavax Technologies</li>
<li>股息捕获策略：你需要知道的事项</li>
<li>Guidewire Software 提供了期待已久的购买机会</li>
<li>什么是欧元 STOXX 50 指数？</li>
<li>最近这三项分析师股票升级背后的原因是什么？</li>
<li>投资石油股票的方式和原因</li>
<li>仍被低估的快速增长公司</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding DVAX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 DVAX 吗？</strong> 访问 HoldingsChannel.com 获取 Dynavax Technologies Co.（纳斯达克代码：DVAX - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=DVAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><p>→ Musk’s new company could top a trillion? (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 马斯克的新公司可能超过一万亿？（来自 Paradigm Press）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDY3Mg" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10672&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Dynavax Technologies right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Dynavax Technologies 吗？</h2>
</div><p>Before you consider Dynavax Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Dynavax Technologies 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Dynavax Technologies 并不在名单上。</p>
</div><p>While Dynavax Technologies currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dynavax Technologies 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

苏黎世州银行出售德纳维制药公司（NASDAQ:DVAX）的股票